These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37429863)

  • 1. ARIH1 activates STING-mediated T-cell activation and sensitizes tumors to immune checkpoint blockade.
    Liu X; Cen X; Wu R; Chen Z; Xie Y; Wang F; Shan B; Zeng L; Zhou J; Xie B; Cai Y; Huang J; Liang Y; Wu Y; Zhang C; Wang D; Xia H
    Nat Commun; 2023 Jul; 14(1):4066. PubMed ID: 37429863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation.
    Wu Y; Zhang C; Liu X; He Z; Shan B; Zeng Q; Zhao Q; Zhu H; Liao H; Cen X; Xu X; Zhang M; Hou T; Wang Z; Yan H; Yang S; Sun Y; Chen Y; Wu R; Xie T; Chen W; Najafov A; Ying S; Xia H
    Nat Commun; 2021 Apr; 12(1):2346. PubMed ID: 33879767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
    Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
    Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors.
    Huang T; Li F; Cheng X; Wang J; Zhang W; Zhang B; Tang Y; Li Q; Zhou C; Tu S
    Front Immunol; 2021; 12():619209. PubMed ID: 33790893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC.
    Taniguchi H; Caeser R; Chavan SS; Zhan YA; Chow A; Manoj P; Uddin F; Kitai H; Qu R; Hayatt O; Shah NS; Quintanal Villalonga Á; Allaj V; Nguyen EM; Chan J; Michel AO; Mukae H; de Stanchina E; Rudin CM; Sen T
    Cell Rep; 2022 May; 39(7):110814. PubMed ID: 35584676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A metal-organic nanoframework for efficient colorectal cancer immunotherapy by the cGAS-STING pathway activation and immune checkpoint blockade.
    Zhang X; Tian H; Chen Y; Liang B; Nice EC; Huang C; Xie N; Zheng S
    J Nanobiotechnology; 2024 Sep; 22(1):592. PubMed ID: 39343911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade.
    Gu SS; Zhang W; Wang X; Jiang P; Traugh N; Li Z; Meyer C; Stewig B; Xie Y; Bu X; Manos MP; Font-Tello A; Gjini E; Lako A; Lim K; Conway J; Tewari AK; Zeng Z; Sahu AD; Tokheim C; Weirather JL; Fu J; Zhang Y; Kroger B; Liang JH; Cejas P; Freeman GJ; Rodig S; Long HW; Gewurz BE; Hodi FS; Brown M; Liu XS
    Cancer Discov; 2021 Jun; 11(6):1524-1541. PubMed ID: 33589424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TTK inhibition activates STING signal and promotes anti-PD1 immunotherapy in breast cancer.
    Hu X; Li G; Li S; Wang Q; Wang Y; Zhang P; Yang T; Yang B; Yu L; Liu Z
    Biochem Biophys Res Commun; 2024 Jan; 694():149388. PubMed ID: 38150917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles.
    Grabosch S; Bulatovic M; Zeng F; Ma T; Zhang L; Ross M; Brozick J; Fang Y; Tseng G; Kim E; Gambotto A; Elishaev E; P Edwards R; Vlad AM
    Oncogene; 2019 Mar; 38(13):2380-2393. PubMed ID: 30518877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precisely Activating cGAS-STING Pathway with a Novel Peptide-Based Nanoagonist to Potentiate Immune Checkpoint Blockade Cancer Immunotherapy.
    Xing Y; Peng A; Yang J; Cheng Z; Yue Y; Liu F; Li F; Liu Y; Liu Q
    Adv Sci (Weinh); 2024 Apr; 11(15):e2309583. PubMed ID: 38233164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ubiquitin E3 ligase FBXO22 degrades PD-L1 and sensitizes cancer cells to DNA damage.
    De S; Holvey-Bates EG; Mahen K; Willard B; Stark GR
    Proc Natl Acad Sci U S A; 2021 Nov; 118(47):. PubMed ID: 34795058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
    Gupta T; Vinayak S; Telli M
    Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of MAN2A1 Enhances the Immune Response to Anti-PD-L1 in Human Tumors.
    Shi S; Gu S; Han T; Zhang W; Huang L; Li Z; Pan D; Fu J; Ge J; Brown M; Zhang P; Jiang P; Wucherpfennig KW; Liu XS
    Clin Cancer Res; 2020 Nov; 26(22):5990-6002. PubMed ID: 32723834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The E3 ubiquitin ligase ARIH1 promotes antiviral immunity and autoimmunity by inducing mono-ISGylation and oligomerization of cGAS.
    Xiong TC; Wei MC; Li FX; Shi M; Gan H; Tang Z; Dong HP; Liuyu T; Gao P; Zhong B; Zhang ZD; Lin D
    Nat Commun; 2022 Oct; 13(1):5973. PubMed ID: 36217001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The E3 ubiquitin ligase ARIH1 protects against genotoxic stress by initiating a 4EHP-mediated mRNA translation arrest.
    von Stechow L; Typas D; Carreras Puigvert J; Oort L; Siddappa R; Pines A; Vrieling H; van de Water B; Mullenders LH; Danen EH
    Mol Cell Biol; 2015 Apr; 35(7):1254-68. PubMed ID: 25624349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNF144A deficiency promotes PD-L1 protein stabilization and carcinogen-induced bladder tumorigenesis.
    Ho SR; Lee YC; Ittmann MM; Lin FT; Chan KS; Lin WC
    Cancer Lett; 2021 Nov; 520():344-360. PubMed ID: 34400221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade.
    Dmello C; Zhao J; Chen L; Gould A; Castro B; Arrieta VA; Zhang DY; Kim KS; Kanojia D; Zhang P; Miska J; Yeeravalli R; Habashy K; Saganty R; Kang SJ; Fares J; Liu C; Dunn G; Bartom E; Schipma MJ; Hsu PD; Alghamri MS; Lesniak MS; Heimberger AB; Rabadan R; Lee-Chang C; Sonabend AM
    Nat Commun; 2023 Mar; 14(1):1566. PubMed ID: 36949040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
    Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
    Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.